Insulin Dosing and Management with NovoLog 70/30

Introduction to NovoLog 70/30

NovoLog 70/30 is a premixed insulin product containing 70% insulin aspart protamine suspension (intermediate-acting) and 30% insulin aspart solution (rapid-acting), according to the American Diabetes Association 1, 2

For insulin-naïve patients, the American College of Endocrinology recommends starting with 10 units or 0.1-0.2 units/kg body weight, typically administered twice daily, 30 minutes before breakfast and dinner 3
The American Association of Clinical Endocrinologists suggests that for patients transitioning from other regimens, dosing should be individualized based on previous insulin requirements and blood glucose levels, with a strength of evidence rated as high 1, 4
Adjust doses based on self-monitoring of blood glucose levels, targeting fasting blood glucose of 90-150 mg/dL, as recommended by the Endocrine Society 3

Monitor for hypoglycemia, which is the most common adverse effect, and evaluate glycemic control every 2 weeks and adjust therapy as needed, according to the American Diabetes Association 3
People with type 2 diabetes generally require higher daily doses (≥1 unit/kg) than those with type 1 diabetes, with a moderate strength of evidence 4
Higher doses increase the risk of hypoglycemia, and careful monitoring is required when using higher doses, as recommended by the European Association for the Study of Diabetes 4

If glycemic targets are not achieved with twice-daily NovoLog 70/30, consider advancing to thrice-daily premixed insulin or switching to a basal-bolus regimen, as suggested by the American College of Endocrinology 2, 3